Literature DB >> 10409468

Basal nitric oxide production is impaired in offspring of patients with essential hypertension.

A S McAllister1, A B Atkinson, G D Johnston, D R Hadden, P M Bell, D R McCance.   

Abstract

There is considerable evidence that endothelium-dependent nitric oxide (NO)-mediated vasodilatation in response to acetylcholine is impaired in essential hypertension, whereas the endothelium-independent response to sodium nitroprusside is normal. More limited data have suggested that there is also reduced vasoconstriction in response to N(G)-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of basal NO release. As it is not known whether endothelial dysfunction in hypertension, if indeed present, is a cause or consequence of the condition, we have studied the normotensive offspring of parents with essential hypertension. Both basal and stimulated vascular responses were examined in 12 normotensive offspring [mean age (+/-S.E.M.) 26.1+/-1.4 years] of parents with essential hypertension and compared with those in 12 age-matched offspring (mean age 25.6+/-1.1 years) of normotensive subjects. Forearm blood flow was measured simultaneously in both arms by venous occlusion plethysmography, both at baseline and during intra-arterial brachial infusion of increasing doses of acetylcholine, sodium nitroprusside, noradrenaline and L-NMMA. There were no significant differences between the groups in the responses to acetylcholine, sodium nitroprusside or noradrenaline. In contrast, the vasoconstrictor response to L-NMMA was significantly blunted in the offspring of hypertensive parents compared with that in the offspring of normotensive parents (P=0.005). Thus endothelial dysfunction, as demonstrated by impaired basal production of NO, is present in subjects at high risk of essential hypertension, and does not occur simply as a consequence of the condition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10409468

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  13 in total

Review 1.  Human endothelial dysfunction: EDRFs.

Authors:  Andreas J Flammer; Thomas F Lüscher
Journal:  Pflugers Arch       Date:  2010-04-12       Impact factor: 3.657

2.  Preserved contribution of nitric oxide to baseline vascular tone in deconditioned human skeletal muscle.

Authors:  Michiel W P Bleeker; Miriam Kooijman; Gerard A Rongen; Maria T E Hopman; Paul Smits
Journal:  J Physiol       Date:  2005-03-31       Impact factor: 5.182

3.  Protein restriction during pregnancy induces hypertension and impairs endothelium-dependent vascular function in adult female offspring.

Authors:  Kunju Sathishkumar; Rebekah Elkins; Uma Yallampalli; Chandra Yallampalli
Journal:  J Vasc Res       Date:  2008-10-29       Impact factor: 1.934

4.  Association of renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study.

Authors:  David Conen; Robert J Glynn; Julie E Buring; Paul M Ridker; Robert Y L Zee
Journal:  J Hypertens       Date:  2008-09       Impact factor: 4.844

5.  Association of urinary N-domain Angiotensin I-converting enzyme with plasma inflammatory markers and endothelial function.

Authors:  Fernanda B Fernandes; Frida L Plavnik; Andressa Ms Teixeira; Dejaldo Mj Christofalo; Sergio A Ajzen; Elisa Ms Higa; Fernanda A Ronchi; Ricardo Cc Sesso; Dulce E Casarini
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

6.  Kidneys in hypertensive rats show reduced response to nitric oxide synthase inhibition as evaluated by BOLD MRI.

Authors:  Luping Li; Pippa Storey; David Kim; Wei Li; Pottumarthi Prasad
Journal:  J Magn Reson Imaging       Date:  2003-06       Impact factor: 4.813

7.  Maternal protein restriction in the rat impairs resistance artery but not conduit artery function in pregnant offspring.

Authors:  Christopher Torrens; Lee Brawley; Alison C Barker; Shigeru Itoh; Lucilla Poston; Mark A Hanson
Journal:  J Physiol       Date:  2002-09-06       Impact factor: 5.182

8.  Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Integr Blood Press Control       Date:  2010-09-28

Review 9.  Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme.

Authors:  Luis Miguel Ruilope; Josep Redón; Roland Schmieder
Journal:  Vasc Health Risk Manag       Date:  2007

Review 10.  Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.

Authors:  Carlos Ferrario
Journal:  Vasc Health Risk Manag       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.